Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty.

@article{Simoons1988ThrombolysisWT,
  title={Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty.},
  author={Marteen L Simoons and Alfred E. R. Arnold and Amadeo Betriu and D P de Bono and Jacques J. Col and Frank Christopher Dougherty and Robert von Essen and Heinz Lambertz and Jacobus C. Lubsen and Bernhard Meier},
  journal={Lancet},
  year={1988},
  volume={1 8579},
  pages={197-203}
}
A randomised trial of 367 patients with acute myocardial infarction was performed to determine whether an invasive strategy combining thrombolysis with recombinant tissue-type plasminogen activator (rTPA), heparin, and acetylsalicylic acid, and immediate percutaneous transluminal coronary angioplasty (PTCA) would be superior to a noninvasive strategy with the same medical treatment but without immediate angiography and PTCA. Intravenous infusion of 100 mg rTPA was started within 5 h after onset… CONTINUE READING